Try our beta test site
112 studies found for:    hemophilia | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Condition: Haemophilia
Intervention:
22 Recruiting Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: AAVrh10FIX
23 Recruiting Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
Condition: Hemophilia B
Intervention:
24 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
25 Recruiting A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
26 Not yet recruiting Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
Conditions: Hemophilia A;   Hemophilia;   Factor VIII Deficiency
Intervention: Drug: Octocog Alfa
27 Recruiting Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Condition: Hemophilia
Intervention:
28 Recruiting Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Condition: Acquired Haemophilia
Interventions: Drug: Steroid + cyclophosphamide;   Drug: Steroid + rituximab
29 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
30 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
31 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
32 Recruiting A Gene Therapy Study for Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: SPK-9001
33 Recruiting Drug Use Investigation of Kovaltry in Hemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
34 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
35 Recruiting Gene Therapy Study in Severe Haemophilia A Patients
Condition: Severe Haemophilia A
Intervention: Genetic: BMN 270
36 Not yet recruiting A Progressive Resistance Training Program in Patients With Haemophilia
Condition: Haemophilia
Interventions: Other: Progressive resistance training;   Other: Normal daily activities
37 Not yet recruiting Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
Condition: Hemophilia A With Inhibitor
Intervention:
38 Recruiting Individualizing Hemophilia Prophylaxis Using Thromboelastography
Condition: Hemophilia A
Intervention: Other: Thromboelastography/Thromboelastometry-Guided Treatment Regimen
39 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
40 Recruiting Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Plasma-derived FVIII/VWF concentrate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.